surmount-1 tirzepatide trial obesity without diabetes For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Presented at ECO 2025: In
Description
J Patient Exp 2024
tirzepatide for weight loss research may find this guide valuable for their academic or scientific endeavors
Always available with any questions I may have
Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
Effective medications are limited
Lose up to 15% of your bodyweight with expert medical guidance for safe, effective, and long-term results.
